| pubmed-article:21339190 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C1334093 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C1333368 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C2613365 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:21339190 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:21339190 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21339190 | pubmed:dateCreated | 2011-2-22 | lld:pubmed |
| pubmed-article:21339190 | pubmed:abstractText | We explored the associations of aberrant DNA methylation patterns in 12 candidate genes with adult glioma subtype, patient survival, and gene expression of enhancer of zeste human homolog 2 (EZH2) and insulin-like growth factor-binding protein 2 (IGFBP2). We analyzed 154 primary glioma tumors (37 astrocytoma II and III, 52 primary glioblastoma multiforme (GBM), 11 secondary GBM, 54 oligodendroglioma/oligoastrocytoma II and III) and 13 nonmalignant brain tissues for aberrant methylation with quantitative methylation-specific PCR (qMS-PCR) and for EZH2 and IGFBP2 expression with quantitative reverse transcription PCR (qRT-PCR). Global methylation was assessed by measuring long interspersed nuclear element-1 (LINE1) methylation. Unsupervised clustering analyses yielded 3 methylation patterns (classes). Class 1 (MGMT, PTEN, RASSF1A, TMS1, ZNF342, EMP3, SOCS1, RFX1) was highly methylated in 82% (75/91) of lower-grade astrocytic and oligodendroglial tumors, 73% (8/11) of secondary GBMs, and 12% (6/52) of primary GBMs. The primary GBMs in this class were early onset (median age 37 years). Class 2 (HOXA9 and SLIT2) was highly methylated in 37% (19/52) of primary GBMs. None of the 10 genes for class 3 that were differentially methylated in classes 1 and 2 were hypermethylated in 92% (12/13) of nonmalignant brain tissues and 52% (27/52) of primary GBMs. Class 1 tumors had elevated EZH2 expression but not elevated IGFBP2; class 2 tumors had both high IGFBP2 and high EZH2 expressions. The gene-specific hypermethylation class correlated with higher levels of global LINE1 methylation and longer patient survival times. These findings indicate a generalized hypermethylation phenotype in glioma linked to improved survival and low IGFBP2. DNA methylation markers are useful in characterizing distinct glioma subtypes and may hold promise for clinical applications. | lld:pubmed |
| pubmed-article:21339190 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21339190 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21339190 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21339190 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21339190 | pubmed:issn | 1523-5866 | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:VandenbergSco... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:NelsonHeather... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:KelseyKarl... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:WienckeJohn... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:TihanTarikT | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:ChangSusan... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:PradosMichael... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:WiemelsJoseph... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:BergerMitchel... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:StokoeDavidD | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:Haas-KoganDap... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:McBrideSeanS | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:WrenschMargar... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:ZhengShichunS | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:MarsitCarmen... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:HousemanE... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:ChristensenBr... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:PatokaJoseph... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:MorrisonZacha... | lld:pubmed |
| pubmed-article:21339190 | pubmed:author | pubmed-author:RamosChristia... | lld:pubmed |
| pubmed-article:21339190 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21339190 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:21339190 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21339190 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21339190 | pubmed:pagination | 280-9 | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:meshHeading | pubmed-meshheading:21339190... | lld:pubmed |
| pubmed-article:21339190 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21339190 | pubmed:articleTitle | DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. | lld:pubmed |
| pubmed-article:21339190 | pubmed:affiliation | Department of Neurological Surgery, University of California-San Francisco, Helen Diller Family Cancer Center, 1450 3rd Street, San Francisco, CA 94158, USA. | lld:pubmed |
| pubmed-article:21339190 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21339190 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:2146 | entrezgene:pubmed | pubmed-article:21339190 | lld:entrezgene |
| entrez-gene:3485 | entrezgene:pubmed | pubmed-article:21339190 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21339190 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21339190 | lld:entrezgene |
